

## **ASX Announcement**

**30 October 2018**

### **HOLISTA COLLTECH LIMITED APPENDIX 4C**

Holista CollTech Limited ("Holista", or the "Company") (ASX CODE: HCT) is pleased to release the Appendix 4C for the quarter ending 30 September 2018.

On 26<sup>th</sup> June 2018, Holista announced a Share Purchase Plan ("SPP"). Shareholders have been extremely supportive with their participation in the SPP and the placement linked to the SPP was fully subscribed. Dr Rajen Manicka and Chan Heng Fai converted what the company owed them to equity. Holista placed 40 million shares at 7 cents worth \$2.8 million as we closed on 25<sup>th</sup> July.

We are thankful to all our shareholders who have been extremely supportive. We also pleased to welcome so many new shareholders.

"We are pleased to again show a positive cash position this quarter", says Dr Rajen Manicka, Managing Director. "This result is on the back of improved operations in Holista's various businesses across the world. The Company has enjoyed significant progress in the production and distribution of Holista's Low GI and Gluten free range of food ingredients into north America and the supplements business continues to grow in its markets. The Company still anticipates growth in the noodle market toward the final quarter of 2018 after overcoming some regulatory challenges in China."

"The Company has worked through some technical matters regarding the production of collagen that are now resolved. In the final quarter of 2018, all orders in Asian region for cosmetic collagen will be fulfilled. The Company is now positioned for new growth in these markets." commented Dr Rajen.

During the next quarter the Company plans to continue its investment into food grade collagen and to finally complete its plans to develop nano sized collagen for food and cosmetic applications.

**For further information, please contact:**

**Corporate Affairs & Business Opportunities**

Dr Rajen Manicka: [rajen.m@holistaco.com](mailto:rajen.m@holistaco.com)  
General Enquiries: [enquiries@holistaco.com](mailto:enquiries@holistaco.com)

**Australia**

283 Rokeby Road  
Subiaco WA 6008  
**P:** +61 8 6141 3500 ; **F:** +61 8 6141 3599

**Malaysia**

12th Floor, Amcorp Trade Centre, PJ Tower  
No. 18, Persiaran Barat off Jalan Timur  
46000, Petaling Jaya, Malaysia  
**P:** +603 7965 2828 ; **F:** +603 7965 2777

**Media and Investor Relations Enquiries**

WeR1 Consultants Pte Ltd  
3 Phillip Street #12-01  
Singapore 048693  
May Barza, [maybarza@wer1.net](mailto:maybarza@wer1.net); **P:** +65 67374844

**About Holista CollTech Ltd**

Holista CollTech Ltd (**Holista**) is a research-driven biotech company and is the result of the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth with extensive operations in Malaysia, Holista is dedicated to delivering first-class natural ingredients and wellness products and leads in research on herbs and food ingredients.

Holista, listed on the Australia Securities Exchange, researches, develops, manufactures and markets “health-style” products to address the unmet and growing needs of natural medicine. Holista’s suite of ingredients is capable of serving the industry to provide low-GI baked products, low sodium salt, low fat fried foods and low calories sugar without compromise in taste, odour and mouth feel. It is the only company to produce sheep (ovine) collagen using patented extraction methods.

# Appendix 4C

## Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

**HOLISTA COLLTECH LIMITED (ASX:HCT)**

ABN

**24 094 515 992**

Quarter ended (Current quarter)

**30 September 2018**

### Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (9 Months) \$A'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers <sup>‡</sup>	1,998	5,690
1.2 Payments for:	-	-
(a) research and development	(45)	(123)
(b) product manufacturing and operating costs <sup>‡</sup>	(1,606)	(2,898)
(c) advertising and marketing	(256)	(469)
(d) leased assets	-	-
(e) staff costs	(787)	(2,322)
(f) administration and corporate costs	(766)	(1,398)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(18)	(62)
1.6 Income taxes (paid) / refunded	(19)	(40)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(1,499)</b>	<b>(1,622)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment <sup>‡</sup>	(15)	(65)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property <sup>‡</sup>	-	(104)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets <sup>‡</sup>	(4)	227
2.3 Cash flows from loans to other entities	(288)	(288)
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material):	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(307)</b>	<b>(230)</b>

<sup>‡</sup> Year to date balances have been adjusted to match the auditor reviewed 2018 June Interim Financial Statements

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 Months) \$A'000
<b>3. Cash flows from financing activities</b>			
3.1 Proceeds from issues of shares		2,362	2,362
3.2 Proceeds from issue of convertible notes		210	210
3.3 Proceeds from exercise of share options		-	-
3.4 Transaction costs related to issues of shares, convertible notes or options		-	-
3.5 Proceeds from borrowings		-	75
3.6 Repayment of borrowings		(7)	(7)
3.7 Transaction costs related to loans and borrowings		-	-
3.8 Dividends paid		-	-
3.9 Other (provide details if material)		-	-
<b>3.10 Net cash from / (used in) financing activities</b>		<b>2,565</b>	<b>2,640</b>
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>			
4.1 Cash and cash equivalents at beginning of quarter/year to date		158	121
4.2 Net cash from / (used in) operating activities (item 1.9 above)		(1,499)	(1,622)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		(307)	(230)
4.4 Net cash from / (used in) financing activities (item 3.10 above)		2,565	2,640
4.5 Effect of movement in exchange rates on cash held		-	8
<b>4.6 Cash and cash equivalents at end of quarter</b>		<b>917</b>	<b>917</b>
<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1 Bank balances		311	158
5.2 Call deposits		606	-
5.3 Bank overdrafts		-	-
5.4 Other (provide details)		-	-
<b>5.5 Cash and cash equivalents at end of quarter</b> (should equal item 4.6 above)		<b>917</b>	<b>158</b>
<b>6. Payments to directors of the entity and their associates</b>		<b>Current quarter \$A'000</b>	
6.1 Aggregate amount of payments to these parties included in item 1.2		89	
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 and 2.5		-	
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2			
In respect to 6.1: Salaries and consulting fees paid to directors and their related parties.			
<b>7. Payments to related entities of the entity and their associates</b>		<b>Current quarter \$A'000</b>	
7.1 Aggregate amount of payments to these parties included in item 1.2		-	
7.2 Aggregate amount of cash flow from loans to these parties included in items 2.3		-	
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2			
Nil			

<b>8. Financing facilities available</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
Add notes as necessary for an understanding of the position		
8.1 Loan facilities	501	501
8.2 Credit standby arrangements	268	259
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Loan facilities-This is secured term loan with RHB bank in Malaysia, interest rates ranging from 4.76% to 6.73%.  
Credit standby arrangements-This is banker acceptance bears interest of 5.15% with CIMB bank in Malaysia. This is secured loan by pledging fixed deposits.

<b>9. Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	72
9.2 Product manufacturing and operating costs	1,026
9.3 Advertising and marketing	178
9.4 Leased assets	-
9.5 Staff costs	759
9.6 Administration and corporate costs	328
9.7 Other (provide details if material):	-
<b>9.8 Total estimated cash outflows</b>	<b>2,363</b>

<b>10. Acquisitions and disposals of business entities</b> (items 2.1(b) and 2.2(b) above)	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets / (deficiency)	-	-
10.5 Nature of business	-	-

## Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Signed: \_\_\_\_\_ Dated: Tuesday, 30 October 2018

Company Secretary

Print name: BRETT FRASER

## Notes

- The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.